SCHEMBL7835222

SCHEMBL7835222

O=C=NS(=O)(=O)c1cccc2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.57
PRSS1 P07477 3/20 0.57
PRSS2 P07478 3/20 0.57
PRSS3 P35030 3/20 0.57
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
HTR6 P50406 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
TSHR P16473 2/20 0.43
HCRTR1 O43613 1/20 0.41
AKR1B1 P15121 1/20 0.40
SCN1A P35498 2/20 0.39
SCN2A Q99250 2/20 0.39
SCN3A Q9NY46 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5655083 0.88 F2 (0.42) F2PRSS1PRSS2PRSS3CA1
SCHEMBL10652362 0.84 F2 (0.56) F2PRSS1PRSS2PRSS3CA1
SCHEMBL6677573 0.82 GAA (0.36) F2PRSS1PRSS2PRSS3CA1
SCHEMBL6580084 0.80 F2 (0.65) F2PRSS1PRSS2PRSS3CA1
SCHEMBL9840763 0.79 F2 (0.68) F2PRSS1PRSS2PRSS3CA1
SCHEMBL5654332 0.77 CYP3A4 (0.43) F2PRSS1PRSS2PRSS3CA1
SCHEMBL11870981 0.77 PRSS1 (0.47) F2PRSS1PRSS2PRSS3CA1
SCHEMBL5610254 0.77 F2 (0.61) F2PRSS1PRSS2PRSS3CA1
SCHEMBL10883679 0.76 CA1 (0.61) F2PRSS1PRSS2PRSS3CA1
SCHEMBL11042682 0.75 MAPT (0.51) F2PRSS1PRSS2PRSS3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10287801-A None JP disclosed
US-9855230-B2 Inhibitors of human immunodeficiency virus replication VIIV Healthcare UK (No.5) Limited (GB) 2018-01-02 US disclosed
US-20170304239-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2017-10-26 US disclosed
WO-2016040084-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-17 WO disclosed
US-9133363-B2 Stabilized urethane based surface coating BLUM HOLGER (CH) 2015-09-15 US disclosed
US-20150011690-A1 STABILIZED URETHANE BASED SURFACE COATING BLUM HOLGER (CH) 2015-01-08 US disclosed
EP-2686358-B1 STABILIZED URETHANE BASED SURFACE COATING BLUM HOLGER (CH) 2014-11-19 EP disclosed
EP-2686358-A1 STABILIZED URETHANE BASED SURFACE COATING Blum, Holger (CH) 2014-01-22 EP disclosed
WO-2013139388-A1 STABILIZED URETHANE BASED SURFACE COATING BLUM HOLGER (CH) 2013-09-26 WO disclosed
EP-0721944-B1 IMIDAZOLIDINE DERIVATIVE AND USE THEREOF SUNTORY LTD (JP) 2001-01-17 EP disclosed
EP-0030141-B1 HERBICIDAL UREAS AND ISOUREAS, PREPARATION, COMPOSITIONS AND USE THEREOF, INTERMEDIATES THEREFOR AND PREPARATION OF SAID INTERMEDIATES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-20 EP disclosed
US-4452627-A HERBICIDE, PLANT GROWTH REGULATOR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-06-05 US disclosed
US-4425155-A 1,2,4-TRIAZINES E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-01-10 US disclosed
US-4421550-A PRE- AND POSTEMERGENCE E. I. DU PONT DE NEMOURS & CO. (US) 1983-12-20 US disclosed
EP-0073562-A2 Herbicidal triazole ureas E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-03-09 EP disclosed
US-4370479-A PLANT GROWTH REGULATOR E. I. DU PONT DE NEMOURS AND COMPANY (US) 1983-01-25 US disclosed
EP-0057546-A2 Sulfonylurea N-oxides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-08-11 EP disclosed
EP-0030141-A2 Herbicidal ureas and isoureas, preparation, compositions and use thereof, intermediates therefor and preparation of said intermediates E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-06-10 EP disclosed
US-4169719-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND CO. (US) 1979-10-02 US disclosed
US-4127405-A TRIAZINYL E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170304239-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2E, POLR2H F2 3861/4885PRSS1 868/4885PRSS2 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.